Protalix BioTherapeutics Inc. (US74365A3095)
XSTU 
Summary
US74365A3095 Chart
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contribution is expected to exceed 50% revenue growth in 2026, improving margin mix and earnings predictability despite near-term volatility.
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress for Protalix, marked by strong commercial execution with our partners and important advances and strategic direction across our clinical and preclinical pipeline," the company's CEO Dror Bashan said.
Protalix BioTherapeutics Inc. (US74365A3095) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protalix BioTherapeutics Inc. ever had a stock split?
Protalix BioTherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dror Bashan CEO | XSTU Exchange | US74365A3095 ISIN |
| US Country | 213 Employees | - Last Dividend | 20 Dec 2019 Last Split | 15 May 1998 IPO Date |
Overview
Protalix BioTherapeutics, Inc. is a notable player in the biopharmaceutical industry, focusing on the development, production, and commercialization of recombinant therapeutic proteins using its innovative ProCellEx plant cell-based protein expression system. The company's global presence extends across the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, among other international markets. Founded in 1993 and having its headquarters in Karmiel, Israel, Protalix BioTherapeutics operates as a subsidiary of Protalix Ltd. It holds strategic agreements and partnerships with influential entities such as Pfizer, Fundação Oswaldo Cruz, and Chiesi Farmaceutici S.p.A, underscoring its collaborative approach to advancing healthcare solutions.
Products and Services
- Elelyso
- Elfabrio
- PRX-115
- PRX-119
A groundbreaking treatment developed by Protalix BioTherapeutics for Gaucher disease, Elelyso showcases the company's capability to address rare and debilitating disorders. This product represents a significant advancement in the field of enzyme replacement therapies, offering patients a plant-cell based, recombinant therapeutic protein alternative.
Another notable entry in Protalix’s portfolio, Elfabrio, has been designed to treat adult patients confirmed to have Fabry disease. This addition emphasizes the company's dedication to expanding its offering of therapeutic solutions for rare genetic diseases, leveraging its proprietary ProCellEx technology to bring innovative treatments to the market.
Currently in Phase I clinical trial, PRX-115 is a pioneer project for Protalix, exploring the potential of plant cell-expressed recombinant PEGylated Uricase in the treatment of gout. This study represents the company's ongoing commitment to the development of novel therapies for widespread conditions utilizing its unique protein expression system.
In the preclinical phase, PRX-119 is a promising venture into developing a plant cell-expressed PEGylated recombinant human DNase I product for the treatment of NETs-related diseases. The initiative to explore treatments for this complex condition illustrates Protalix BioTherapeutics' dedication to leveraging its platform for addressing a broad spectrum of diseases.
